FIGURE 9.
Graphical abstract. In ob/ob mice model, ponatinib inhibits obesity-induced adipose tissue macrophage inflammatory transformation, thereby inhibiting obesity adipose tissue inflammation and insulin resistance, accompanied by amelioration of ectopic lipid deposition in peripheral blood and liver.